SUMmARY In studying the effects of 2-deoxy-D-glucose (2-DG) on the vagus nerve in preoperative patients with duodenal ulcer we have concluded that (1) in initiating gastric acid secretion 2-DG produces a response that is reproducible after 30 days; (2) 2-DG when given in a dose of 40 mg/kg intravenously produces a glucopenic state that appears safe in an otherwise healthy patient.
SUMmARY In studying the effects of 2-deoxy-D-glucose (2-DG) on the vagus nerve in preoperative patients with duodenal ulcer we have concluded that (1) in initiating gastric acid secretion 2-DG produces a response that is reproducible after 30 days; (2) 2-DG when given in a dose of 40 mg/kg intravenously produces a glucopenic state that appears safe in an otherwise healthy patient.
We consider that 2-DG is a worthwhile agent in the investigation of the duodenal ulcer patient.
2-Deoxy-D-glucose (2-DG) has been used for several years as a vagal stimulant to induce gastric acid secretion both in animals Eisenberg, Emas, and Grossman, 1966) and in man (Duke, Hirschowitz, and Sachs, 1965) . Among the aspects of its activity as yet unreported is the reproducibility of response in the individual patient. This study investigates this problem and employs gastric function tests in duodenal ulcer patients. Duplicate tests carried out on each patient with an interval of 30 days were compared with respect to peak acid output and two-hour total acid output. The nature of any side effects occurring during the tests was also evaluated in the light of reports of patients developing atrial fibrillation (Duke et al, 1965) , jaundice and hypothermia (Thomas and Duthie, 1968) , and the theoretical possibility of irreversible hypoglycaemia (Himsworth and Colin-Jones, 1969 The paired results for acid secretion showed several noteworthy features: (a) The values for peak acid output (PAO) had a highly significant correlation between the tests (p < 0'001) (fig 2) In considering the actions of 2-DG it is worth recalling that glucose passes through the blood/brain barrier by an active transport system whose capacity is so limited that the rate of glucose transfer is almost maximal at fasting plasma glucose concentrations. Passive diffusion does not occur until the plasma glucose level is greatly elevated (Crone, 1965) .
As Agnew and Crone (1967) have reported that glucose and 3-0-methyl glucose have an equal affinity for the blood/brain glucose transport system, and Himsworth and Colin-Jones (1969) have shown that both glucose and 3-0-methyl glucose inhibit the cellular glucopenia usually caused by 2-DG, it is reasonable to assume that glucose and 2-DG compete for this same system.
Once within the cell 2-DG is phosphorylated to 2-DG-6-phosphate (Sols and Crane, 1954) , and the resultant hypothalamic glucopenia (Colin-Jones and Himsworth, 1970) excites the dorsal vagal nuclei (Kerr and Preshaw, 1969) with an increase in volume and all components of gastric juice. The extracellular glucose level rises and the hypothalamic glucopenia is gradually reversed as glucose passively diffuses across the blood/brain barrier. The 2-DG is then excreted unchanged in the urine.
Previous reluctance to use 2-DG as a vagal stimulant has stemmed mainly from three published reports: (1) Duke et al (1965) had one patient in whom atrial fibrillation developed following administration of 2-DG, the plasma potassium concentration being 2-7 m equiv/l at this time. (2) In 1968 Thomas and Duthie in a study comparing 2-DG and insulin in 37 patients found that three patients developed an exaggerated hypoglycaemic reaction with the body temperature falling to 89'F with the production of a semicomatose state in one patient. They also quoted unpublished tests in which 2-DG given on the same day as surgery was undertaken might have caused 'mild liver cell damage' in two patients. (3) Himsworth and Colin-Jones (1969) give two theoretical dangers of 2-DG: first, a state of 'profound hypoglycaemia' may be produced in patients with a lower than normal fasting plasma glucose; secondly, reversal of the glucopenia with 50 % glucose solution may produce plasma hyperosmolarity.
Dealing with these reports in order, any fall in serum potassium concentration below normal may induce instability of myocardial conduction. However, as long as the potassium concentration is normal before hypoglycaemia is induced and the test is not continued for more than the two hours of a normal gastric function test, a drop outside the normal range should not occur. The patient quoted by Duke et al appears to have been hypoglycaemic for at least four hours.
The fall in body temperature, due probably to excessive sweating, may be minimized by conducting the tests in a warm room in which the air is still, and by covering the patient with an air-holding cellular type blanket. No patient among the group who sweated during the test showed a drop in body temperature greater than 0-5°C in this report. The patient who became semicomatose with 2-DG and who also exhibited severe hypoglycaemic symptoms with insulin (Thomas and Duthie, 1968) illustrates the point that it is essential to know that the fasting glucose level is within normal limits before giving any glucopenic agent. We knew this value in each patient before proceeding with the test. Armed with this result the state of profound hypoglycaemia postulated by Himsworth and Colin-Jones (1969) should never occur.
It is difficult to comment on the evidence for hepatotoxicity quoted by Thomas and Duthie (1968) without fuller knowledge of the cases, but it would seem unwise to anaesthetize a glucopenic patient. However, Franks and Griffen (1968) (Duke et al, 1965; Johnston, Thomas, Checketts, and Duthie, 1967; Thomas and Duthie, 1968 ) but certainly not in amounts which would cause the elevation of plasma glucose to the levels quoted by Himsworth and Colin-Jones (1969) in their rat experiments, as their assessment of reversal of hypoglycaemia was the reduction in gastric acid secretion. Plasma hyperosmolarity should not be encountered in the human subject. The potential use of 2-DG is in providing a safe, effective alternative to the insulin-induced glucopenia in examining both acid secretion and vagal integrity in the duodenal ulcer patient.
Several authors have reported upon the use of 2-DG as a test of complete vagal section following vagotomy (Johnston et al, 1967 ; Thomas and Duthie, 1968; Stalder, Schultheiss, and Allgower, 1972) and have indicated the superiority of 2-DG over insulin. The production of acid is more rapid and greater in magnitude with 2-DG (Emis and Borg, 1972) and the interpretation of the results unconfused by the 'early' and 'late' responses encountered when using insulin (Stalder et al, 1972) .
The short-term reproducibility of the insulin test has been established (Gillespie, Elder, Gillespie, Kay, and Crean, 1970) and we have demonstrated the same with 2-DG in the unoperated patient. There seems no reason to suppose that the postvagotomy patient would show a deviation from this reproducibility although the total acid output levels in these patients would be much reduced.
It should be emphasized that in these tests 2-DG conditions. This is also true during insulin-induced glucopenia.
We feel that our results, together with those of others published recently (Stalder et al, 1972; Popiela, Szafran, and Szafran, 1972) 
